PRISM BioLab Co Ltd
PRISM BioLab maintains a strong liquidity position, with cash and equivalents amounting to ¥29.6 billion, significantly exceeding its total liabilities of ¥7.75 billion, resulting in a current ratio of 3.95. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure with no leverage. Despite its strong liquidity, the company reported a net loss of ¥18.25 billion for the period, with an operating loss of ¥19.4 billion. Return on equity (ROE) was -7.89%, and return on assets (ROA) was -5.91%, both significantly below the industry median for biotechnology and medical research firms. The company's revenue for the period was ¥73.41 billion, but there is no disclosed breakdown of revenue by geographic region or business segment. Given the lack of segmental data, it is not possible to assess geographic or product concentration risk. Looking ahead, the company's growth trajectory is uncertain. While it generated positive operating cash flow of ¥340.14 billion, capital expenditures were relatively modest at ¥10.9 million. There is no disclosed revenue growth or decline in the outlook, and no specific guidance for the next fiscal ye
Business. PRISM BioLab Co Ltd is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in Japan and primarily listed on the Tokyo Stock Exchange under the ticker symbol 206A.T. Specific details regarding its operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PRISM BioLab Co Ltd is a biotechnology and medical research company engaged in healthcare diagnostics. The firm is headquartered in Japan and primarily listed on the Tokyo Stock Exchange under the ticker symbol 206A.T. Specific details regarding its operating segments and geographic revenue mix are not available.
PRISM BioLab maintains a strong liquidity position, with cash and equivalents amounting to ¥29.6 billion, significantly exceeding its total liabilities of ¥7.75 billion, resulting in a current ratio of 3.95. The company has no long-term debt, and its debt-to-equity ratio is 0.0, indicating a conservative capital structure with no leverage.
Despite its strong liquidity, the company reported a net loss of ¥18.25 billion for the period, with an operating loss of ¥19.4 billion. Return on equity (ROE) was -7.89%, and return on assets (ROA) was -5.91%, both significantly below the industry median for biotechnology and medical research firms.
The company's revenue for the period was ¥73.41 billion, but there is no disclosed breakdown of revenue by geographic region or business segment. Given the lack of segmental data, it is not possible to assess geographic or product concentration risk.
Looking ahead, the company's growth trajectory is uncertain. While it generated positive operating cash flow of ¥340.14 billion, capital expenditures were relatively modest at ¥10.9 million. There is no disclosed revenue growth or decline in the outlook, and no specific guidance for the next fiscal year.
The company's risk profile is currently low, with no immediate liquidity or dilution flags detected. The absence of long-term debt and the high cash balance reduce financial risk. However, the significant net loss and negative returns suggest operational challenges that could affect long-term sustainability.
Recent filings and transcripts do not indicate any major strategic shifts or operational disruptions. The company appears to be maintaining its current operations without significant new initiatives or capital commitments.
- PRISM BioLab has a strong liquidity position with no long-term debt and a current ratio of 3.95.
- The company reported a net loss of ¥18.25 billion and negative returns on equity and assets.
- There is no disclosed segmental or geographic revenue breakdown, limiting visibility into concentration risk.
- The company's growth trajectory is unclear, with no specific guidance for the next fiscal year.
- The risk profile is currently low, with no immediate liquidity or dilution concerns.
Bull / Bear case
Generated · model-assistedRevenue surged 121.6% year-over-year to JPY 677.3 million, demonstrating significant top-line growth momentum.
The company maintains zero long-term debt, providing a debt-free balance sheet that mitigates financial leverage risks.
Net income improved by 20.6% year-over-year, signaling a positive trajectory in profitability despite ongoing losses.
Dilution and liquidity risks are assessed as low, suggesting stable capital structure and adequate market trading conditions.
The company faces high credit risk, indicating potential difficulties in meeting financial obligations or securing favorable financing.
Cash conversion ratio of -1.86 places the firm in the bottom quartile of its biotechnology peer cohort.
Net margin of -2.49% and operating margin of -2.64% both trail the respective cohort medians, reflecting weaker profitability.
Free cash flow remains deeply negative at JPY -901.4 million, highlighting persistent cash burn despite revenue growth.
In focus — financials by report
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- PRISM BioLab Co Ltd Market data — financials · 2026-05-26